ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
China flag China · Delayed Price · Currency is CNY
8.76
-0.34 (-3.74%)
Sep 10, 2026, 3:04 PM CST

SHE:300254 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
848.93868.17842.33792.42824.84924.94
Other Revenue
0.742.624.286.894.155.43
849.67870.79846.61799.31829930.37
Revenue Growth
3.81%2.86%5.92%-3.58%-10.90%9.71%
Cost of Revenue
288.14285.24283.21259.45251.21290.06
Gross Profit
561.53585.54563.39539.86577.79640.32
Selling, General & Admin
404.14416.12428.41453.44534.1603.92
Research & Development
47.6650.856.5349.9754.5257.12
Other Operating Expenses
3.864.49-0.374.8612.0912.77
Operating Expenses
461.26476.48490.35507.84601.43668.48
Operating Income
100.27109.0673.0432.02-23.64-28.16
Interest Expense
-9.71-21.63-16.98-33.16-46.06-49.17
Interest & Investment Income
3.934.225.8624.632.5515.74
Earnings From Equity Investments
-----3.43-
Currency Exchange Gain (Loss)
00-0.010.620
Other Non Operating Income (Expenses)
5.1316.1119.4918.51-2.08-0.2
EBT Excluding Unusual Items
99.62107.7681.4242-72.05-61.8
Impairment of Goodwill
---4.26-4.1-19.58-19.6
Gain (Loss) on Sale of Investments
-21.91-18.93----
Gain (Loss) on Sale of Assets
1.058.947.5118.80.69-0.37
Asset Writedown
-1.57-0.43-1.41-1.4-28.82-12.08
Other Unusual Items
-2.76-6.54-2.62-0.0229.7428.37
Pretax Income
74.4290.7980.6455.28-90.02-65.48
Income Tax Expense
22.634.365.886.557.99.07
Earnings From Continuing Operations
51.8256.4474.7648.73-97.92-74.55
Minority Interest in Earnings
-23.07-31.59-32.57-23.53-20.6-16.89
Net Income
28.7624.8542.1925.2-118.52-91.44
Net Income to Common
28.7624.8542.1925.2-118.52-91.44
Net Income Growth
217.10%-41.10%67.45%---
Shares Outstanding (Basic)
246243242242237228
Shares Outstanding (Diluted)
249245242242237228
Shares Change
3.54%1.15%0.20%1.89%4.00%6.92%
EPS (Basic)
0.120.100.170.10-0.50-0.40
EPS (Diluted)
0.120.100.170.10-0.50-0.40
EPS Growth
206.25%-41.77%67.11%---

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
12662.4519.443.948.0959.99
Free Cash Flow Per Share
0.510.260.080.020.200.26
Gross Margin
66.09%67.24%66.55%67.54%69.70%68.82%
Operating Margin
11.80%12.52%8.63%4.00%-2.85%-3.03%
Profit Margin
3.38%2.85%4.98%3.15%-14.30%-9.83%
Free Cash Flow Margin
14.83%7.17%2.30%0.49%5.80%6.45%
EBITDA
152.44160.06124.5584.6134.6635.55
EBITDA Margin
17.94%18.38%14.71%10.59%4.18%3.82%
D&A For EBITDA
52.175151.5152.5958.363.71
EBIT
100.27109.0673.0432.02-23.64-28.16
EBIT Margin
11.80%12.52%8.63%4.00%-2.85%-3.03%
Effective Tax Rate
30.37%37.84%7.29%11.85%--
Revenue as Reported
497.79870.79846.61799.31829930.37
Advertising Expenses
-21.3812.745.674.888.44